Singapore Pharmaceuticals & Healthcare Report Q3 2015 - New Market Study Published

Singapore will remain a highly attractive manufacturing base for international pharmaceutical companies due to minimal levels of operational risks and the government's support for the industry. The pharmaceutical industry has been a key pillar of the country's economy and we believe its importance will continue to grow as traditional drivers such as electronic manufacturing slow.

Headline Expenditure Projections

* Pharmaceuticals : SGD1.041bn (USD822mn) in 2014 to SGD1.097bn (USD836mn) by 2015; +5.4% in local currency terms and +1.7% in USD terms.
* Healthcare: SGD19.31bn (USD15.24bn) in 2014 to SGD20.97bn (USD15.97bn) by 2015; +8.6% in local currency terms and +4.8% in USD terms.

Risk/Reward Index

Singapore is ranked eighth out of 19 other Asia Pacific markets (scoring 62.1 out of a maximum 100) on BMI's Pharmaceutical Risk/Reward Index for Q215. The country's above average score on country rewards (scoring 16.8 out of 21.0) with the highest score for risk (28.1 out of 35) in the region is weighed down by the limited industry rewards (17.2 out of 44.0) due to the country's small population.

Full Report Details at
- http://www.fastmr.com/prod/1004022_singapore_pharmaceuticals.aspx?afid=301

Key Trends And Developments

* In November 2014, the Ministry of Health is seeking feedback on a new Human Biomedical Research Bill that will formalise standards for biomedical research. Some of the research that will be covered include tissue graphs, new surgical techniques and diagnostic imaging.
* In December 2014, the Singapore Eye Research Institute (SERI) and Singapore Chung Hwa Medical Institution are partnering for an upcoming clinical trial which will consider the effectiveness of Traditional Chinese Medicine in alleviating dry eye symptoms. The study will involve 150 patients, aged 40 to 85.
* In January 2015, the Singapore Parliament passed the MediShield Life Scheme Bill which will provide universal insurance coverage for all Singaporeans. In the first year, all citizens will receive a 90% subsidy on the net increase in premium for the first year and a...

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Estonia Pharmaceuticals & Healthcare Report Q3 2015
- Bahrain Pharmaceuticals & Healthcare Report Q3 2015
- United States Pharmaceuticals & Healthcare Report Q3 2015
- South Korea Pharmaceuticals & Healthcare Report Q3 2015
- Jordan Pharmaceuticals & Healthcare Report Q3 2015